Recursion Pharmaceuticals, Inc. (RXRX) Financials

RXRX Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 653.7 million 190.3 million
2023-09-30 630.8 million 192.9 million
2023-06-30 666.7 million 197.7 million
2023-03-31 627.4 million 197.2 million

RXRX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -76.5 million 16.1 million
2023-09-30 -73.7 million 16.8 million
2023-06-30 -71.4 million 11.8 million
2023-03-31 -78.7 million 8.8 million

RXRX Net Income

No data available :(

RXRX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 394.8 million - 49.5 million
2023-09-30 387.3 million - 49.7 million
2023-06-30 405.9 million 1.2 million 51.1 million
2023-03-31 473.1 million 1.2 million 51.2 million

RXRX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 233.2 million
2023-09-30 214.3 million
2023-06-30 201.4 million
2023-03-31 191.6 million

RXRX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 2.4 million 66.1 million 30.5 million -
2023-09-30 827000 70.0 million 29.2 million -
2023-06-30 4.0 million 55.1 million 28.3 million -
2023-03-31 5.3 million 46.7 million 22.9 million -

RXRX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 10.9 million 23.5 million
2023-09-30 10.1 million 10.9 million
2023-06-30 11.0 million 9.4 million
2023-03-31 12.1 million 12.4 million

RXRX

Price: $9.08

52 week price:
4.54
16.75

Earnings Per Share: -1.58 USD

P/E Ratio: -6.25

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 732400

Market Capitalization: 2.1 billion

Links: